Compass Therapeutics, Inc. (CMPX)
$2.40+0.00%Close
BUYRECOVERY · day 12
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $432M
- Avg volume
- 7.6M
- Beta
- 0.82
- P/E (TTM)
- -5.78
- Short % float
- 41.10%
- Days to cover
- 17.6
- SI change
- +1.5%
- 1W
- +3.90%
- 1M
- +15.94%
- 3M
- +15.94%
- YTD
- -53.58%
- vs SPY 1W
- +5.09%
- vs SPY 1M
- +12.62%
- vs SPY 3M
- +13.55%
- vs SPY YTD
- -65.33%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- CGEMBUYCullinan Therapeutics, Inc.BULLQ 6$21.82+0.65%
- ENTXBUYEntera Bio Ltd.RECOVERYQ 10$3.42+5.88%
- IMNMBUYImmunome, Inc.BULLQ 22$28.01-1.79%
- PVLASELLPalvella Therapeutics, Inc.BEARQ 14$145.75+2.61%
- SLSBUYSELLAS Life Sciences Group, Inc.RECOVERYQ -8$14.33-7.31%
- UNCYBUYUnicycive Therapeutics, Inc.RECOVERYQ -4$5.34-5.15%
- XENESELLXenon Pharmaceuticals Inc.BEARQ 26$60.56-0.35%
- CNTXBUYContext Therapeutics Inc.CRISISQ -15$0.47-6.00%
- KYTXBUYKyverna Therapeutics, Inc.RECOVERYQ -16$8.24-2.14%
- SIONSELLSionna Therapeutics, Inc.CRISISQ -31$5.59+5.67%
- VERASELLVera Therapeutics, Inc.RECOVERYQ 23$33.72+4.49%
- TEVABUYTeva Pharmaceutical Industries LimitedBULLQ 11$36.93-1.10%
Industry peers
FMP comparable companies · ranked by market cap
- KALVBUYKalVista Pharmaceuticals, Inc.$1.4BBULLQ 9$27.00+0.00%
- OMERBUYOmeros Corporation$1.3BBULLQ 18$18.63+0.26%
- CRVSBUYCorvus Pharmaceuticals, Inc.$1.2BRECOVERYQ 14$14.33-2.56%
- LXRXSELLLexicon Pharmaceuticals, Inc.$968MBEARQ 6$2.18+0.87%
- FDMTBUY4D Molecular Therapeutics, Inc.$842MRECOVERYQ 5$16.10-2.78%
- MNPRBUYMonopar Therapeutics Inc.$743MCRISISQ 14$110.88+3.38%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 7
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-23.2%
REV YoY-
ROE-38.7%
EPS YoY-
ROA-38.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-5.78
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B2.70
P/FCF-
EV/EBITDA-5.59
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.80
ALTMAN Z-
CURR RATIO11.22
ND/EBITDA-
BETA0.82
